Ducrocq G, Gonzalez-Juanatey JR, Puymirat E, et al. - Since there is lack of clarity regarding the optimal transfusion strategy in patients suffering from acute myocardial infarction and anemia, therefore, researchers conducted this open-label, noninferiority, randomized trial to ascertain if a restrictive transfusion strategy would be clinically noninferior to a liberal strategy. A total of 668 patients with myocardial infarction and hemoglobin concentration between 7 and 10 g/dL were included and were randomized to a restrictive (transfusion triggered by hemoglobin ≤ 8; n = 342) or a liberal (transfusion triggered by hemoglobin ≤ 10 g/dL; n = 324) transfusion strategy. Major adverse cardiovascular events (MACE; composite of all-cause mortality, stroke, recurrent myocardial infarction, or emergency revascularization prompted by ischemia) at 30 days was assessed as primary clinical outcome. Noninferiority needed that the upper bound of the 1-sided 97.5% CI for the relative risk of the primary outcome be less than 1.25. Findings revealed that a noninferior rate of MACE following 30 days was provided by a restrictive vs a liberal transfusion strategy in patients suffering from acute myocardial infarction and anemia. However, the CI included what may be a clinically essential harm.